If your plan denied Zepbound and offered Wegovy instead, or told you to fill out a "medical necessity" form, you're being routed toward a formulary exception whether or not anyone used that term. It's the mechanism plans use to decide whether a drug outside their preferred list is worth covering for one specific patient, and for Zepbound in 2026, it's one of the most frequently filed exception types in the country.
That's not an accident. A wave of major formulary changes over the past year has left a large share of commercially insured patients needing to actively request Zepbound rather than simply filling it. This guide walks through exactly how that request works, what has to be in it, how long it takes by plan type, and what your options are if it doesn't go your way the first time.
What a Formulary Exception for Zepbound Actually Means
Every health plan maintains a formulary — a list of drugs it covers, organized into cost-sharing tiers. When a drug isn't on that list, or is on the list but behind a restriction such as step therapy, patients don't automatically get access. Instead, the plan offers an exceptions process: a formal channel for a prescriber to argue that the specific patient in front of them needs the specific drug being requested, not the plan's preferred alternative.
For Zepbound, this usually plays out one of two ways in 2026:
- Zepbound isn't on the formulary at all — common on plans that moved to Wegovy as their preferred GLP-1 — and the request is a true off-formulary (non-formulary) exception.
- Zepbound is on the formulary but behind step therapy — meaning you must try and fail a preferred drug like Wegovy first — and the request is a step therapy exception rather than a formulary exception, though patients and even some plan representatives use the terms loosely.
Why this distinction matters: the documentation that wins a non-formulary exception (proving Zepbound belongs in the drug class at all) is different from what wins a step therapy exception (proving the required first-line drug won't work or has already failed for you). Filing the wrong type of request, or filing generic paperwork that doesn't match which restriction actually applies, is one of the most common reasons these requests stall.
Why Zepbound Exception Requests Are So Common Right Now
The current spike in Zepbound exception requests traces back to a specific formulary decision. CVS Caremark, which manages pharmacy benefits for a large share of U.S. commercial plan members, removed Zepbound from its Standard Control, Advanced Control, and Value formularies effective July 1, 2025, making Wegovy the sole preferred GLP-1 for weight management on those formularies. Patients who were stable on Zepbound were generally expected to switch to Wegovy or file an exception.
That decision is now reversing, but not immediately. CVS Caremark announced on May 28, 2026, that Zepbound will return to its standard commercial formularies as a co-preferred option alongside Wegovy, effective October 1, 2026. Until that date, patients on affected plans generally still need a formulary exception to get Zepbound covered without switching.
| Date | What Changed |
|---|---|
| July 1, 2025 | Zepbound removed from Standard, Advanced Control, and Value formularies; Wegovy becomes sole preferred GLP-1 |
| January 1, 2026 | CVS Caremark confirms no further GLP-1 formulary changes for the new plan year |
| April 2026 | Lilly and the federal government announce reduced Zepbound pricing for Medicare beneficiaries |
| May 28, 2026 | CVS Caremark announces Zepbound will return as a co-preferred option |
| June 2, 2026 | Foundayo (orforglipron), Lilly's oral GLP-1, added to the CVS Caremark formulary |
| October 1, 2026 | Zepbound reinstated on formulary at the same tier as Wegovy for participating plans |
Other pharmacy benefit managers and self-funded employer plans made independent decisions that don't necessarily follow CVS Caremark's timeline, so your plan's exact status depends on which PBM administers your pharmacy benefit and what your specific employer chose. Several class-action lawsuits have also been filed alleging that the original removal was driven more by manufacturer rebate arrangements than by clinical evidence — those cases remain in litigation and don't change what you need to do today to get coverage.
Formulary Exception vs Prior Authorization vs Step Therapy Exception
These terms get used interchangeably by patients and sometimes by insurance representatives, but they aren't the same request, and mixing them up slows your case down.
| Request Type | What It's For | What You Must Prove |
|---|---|---|
| Prior Authorization | Routine approval required before a covered drug is dispensed | You meet the plan's stated clinical criteria (BMI, diagnosis, etc.) |
| Formulary Exception (Non-Formulary) | The drug isn't on your plan's covered list at all | The formulary alternative(s) won't work as well for you specifically |
| Tiering Exception | The drug is covered, but at an expensive specialty tier | You need the drug at a lower cost-sharing tier due to cost burden or intolerance to preferred-tier options |
| Step Therapy Exception | You're required to try a preferred drug (e.g. Wegovy) before Zepbound | You've already tried and failed the required drug, or it's contraindicated for you |
When a Formulary Exception Works — and When It Can't
This is the single most important distinction in this entire process, and it's the one most patients get wrong before they start.
| Your Plan's Situation | Can a Formulary Exception Help? |
|---|---|
| Zepbound isn't on formulary, but Wegovy or another GLP-1 is covered | Yes — this is exactly what the exceptions process is for |
| Zepbound requires step therapy (try Wegovy first) | Yes, if you can document why the required drug won't work |
| You have OSA and Zepbound is the only approved GLP-1 for that diagnosis | Yes — often the strongest exception argument available |
| Your plan document categorically excludes all anti-obesity medications | No — this is a benefit exclusion, not a formulary placement issue |
| Your employer plan doesn't cover any weight-management drug class at all | No — same reason; there's no formulary decision to appeal |
How to tell which situation you're in: check your plan's Summary of Benefits or ask HR whether "anti-obesity medications" or "weight loss drugs" are listed as an excluded benefit category. If they are, no amount of clinical documentation changes that — the fix has to happen at the plan-design level during your employer's next renewal, not through an individual exception request.
Required Documentation for a Strong Request
Exception requests get denied far more often for incomplete documentation than for genuinely failing clinical criteria. Assemble these before your prescriber submits anything.
| Document | Why It Matters |
|---|---|
| Current BMI and weight history | Establishes baseline medical necessity for the drug class |
| Documented weight-related comorbidities | Type 2 diabetes, hypertension, OSA, or cardiovascular disease strengthen the case |
| Prior GLP-1 or weight-management drug trial history | Shows what's already been tried, and why it didn't work (intolerance, insufficient response, contraindication) |
| Sleep study results (if applicable) | Required to document OSA severity if requesting under the OSA indication |
| Prescriber's written supporting statement | The core clinical narrative explaining why Zepbound specifically is medically necessary for this patient |
| Denial letter or formulary confirmation | Confirms the exact restriction being appealed (non-formulary, tiering, or step therapy) |
Building the Strongest Possible Clinical Argument
- State plainly why the formulary alternative (usually Wegovy) is expected to be less effective or poorly tolerated for this specific patient — not GLP-1s in general.
- If treating OSA, explicitly cite that Zepbound holds an FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, and that no alternative GLP-1 shares that specific indication.
- Include objective measurements (BMI, A1C, sleep study AHI score) rather than general descriptions of symptoms.
- Document any prior adverse reaction to semaglutide (the active ingredient in Wegovy) by name and date, if applicable.
- Keep the statement specific to this patient's clinical history — generic templated language is the single most common reason for a first-pass denial.
Step-by-Step: How to Request the Exception
Get your denial or formulary status in writing
Request or locate the exact denial letter or formulary lookup showing Zepbound isn't covered, or is behind step therapy. This document tells you and your prescriber exactly which restriction you're appealing.
Confirm which form your plan requires
Most plans accept either a Coverage Determination Request Form (standard for Medicare Part D) or a plan-specific formulary exception form. Some accept a prescriber's letter in place of a form — call member services to confirm before submitting.
Have your prescriber draft the supporting statement
This is the clinical core of the request. It needs to explain, in specific terms, why the formulary alternative won't work for this patient and why Zepbound is medically necessary.
Attach all supporting documentation
Include BMI history, comorbidity documentation, prior treatment history, and sleep study results if relevant. Submit everything in a single package rather than piecemeal, which slows processing.
Request expedited review if clinically appropriate
If waiting for a standard decision could seriously harm your health — for example, unmanaged severe OSA — your prescriber can request an expedited review, which carries a much shorter decision deadline.
Confirm receipt and track the decision deadline
Note the date your plan received the prescriber's supporting statement — that's when the countdown for a decision legally starts, not the date you mailed or submitted it.
Commercial Plans vs Medicare Part D: Timelines Compared
| Plan Type | Standard Decision Deadline | Expedited Decision Deadline |
|---|---|---|
| Medicare Part D | 72 hours from receipt of supporting statement | 24 hours from receipt of supporting statement |
| Medicare Part D — First Appeal (Redetermination) | 7 days | 72 hours |
| Commercial/ERISA employer plan — urgent care claim | As soon as possible, generally no later than 72 hours | Same — urgent claims already carry the shortest deadline |
| Commercial/ERISA employer plan — non-urgent pre-service claim | Generally within 15 days | Not applicable — reserved for non-urgent requests |
| State-regulated fully insured plan | Varies by state; often similar to or faster than the ERISA standard | Varies by state |
Practical tip: the "urgent" versus "non-urgent" classification is often the deciding factor in how fast you hear back on a commercial plan. If your prescriber believes a delay could seriously jeopardize your health or ability to function, say so explicitly in the request — plans are required to treat that determination seriously, and it's the mechanism that gets you the 72-hour deadline instead of the 15-day one.
Medicare and Zepbound: OSA Coverage vs the GLP-1 Bridge
Medicare's relationship with Zepbound is more complicated than commercial insurance, because federal law historically excludes weight-loss drugs from Part D coverage. Two separate pathways now exist, and confusing them is a common — and costly — mistake.
| Pathway | What It Covers | Eligibility | Cost |
|---|---|---|---|
| Standard Part D — OSA Indication | Zepbound prescribed specifically for moderate-to-severe obstructive sleep apnea with obesity | Confirmed OSA diagnosis via sleep study, plus obesity; plan formulary and prior authorization rules still apply | Standard Part D cost-sharing, subject to the $2,000 annual out-of-pocket cap |
| Standard Part D — Type 2 Diabetes | Tirzepatide covered under the Mounjaro brand for diabetes | Type 2 diabetes diagnosis | Standard Part D cost-sharing |
| Medicare GLP-1 Bridge (Demonstration) | Zepbound KwikPen for weight loss specifically, outside standard Part D rules | Meets BMI-based eligibility criteria; requires prior authorization; live July 1, 2026 – December 31, 2027 | Flat $50/month copay regardless of dose |
Standard Medicare Part D does not cover Zepbound for weight loss alone — this exclusion is written into federal law, not plan policy, so a formulary exception request cannot override it through your regular Part D plan. If you're pursuing coverage for weight management rather than OSA or diabetes, the GLP-1 Bridge demonstration — not a formulary exception — is the correct pathway, and it runs on a separate prior authorization process through your plan.
If you have both OSA and are pursuing weight-loss coverage, ask your prescriber to be precise about which diagnosis is driving which prescription — mixing the two in a single request can create confusion that delays both pathways.
Real-World Examples
| Detail | Outcome |
|---|---|
| Situation | Patient stable on Zepbound for 14 months; CVS Caremark removed it from formulary July 2025 |
| Documentation submitted | Weight and A1C trend data showing continued improvement on Zepbound; prior trial of a GLP-1 with intolerable nausea |
| Result | Approved for continued Zepbound coverage under a non-formulary exception, valid through end of plan year |
| Detail | Outcome |
|---|---|
| Situation | Plan required a trial of Wegovy before approving Zepbound; patient has moderate-to-severe OSA with obesity |
| Documentation submitted | Sleep study confirming OSA severity; note that Wegovy carries no FDA approval for OSA, only Zepbound does |
| Result | Step therapy waived; approved directly for Zepbound based on the OSA-specific indication argument |
| Detail | Outcome |
|---|---|
| Situation | Self-funded employer plan excludes "anti-obesity medications" as a category in the plan document |
| Documentation submitted | Full clinical file, including comorbidities and prior treatment history |
| Result | Denied — plan confirmed the denial was a benefit exclusion, not a formulary decision, so no exception could be granted; patient's only paths forward were the employer's next open enrollment or a manufacturer cash-pay option |
Decision Tree: Is a Formulary Exception the Right Move?
Start Here
Was Zepbound denied because it's not on the formulary, or because of step therapy?
Your plan document excludes all anti-obesity drugs
This is a category exclusion, not a formulary placement issue
Formulary Exception Won't Help
Explore open enrollment plan changes or manufacturer cash-pay pricing instead
Zepbound is off-formulary or behind step therapy
The drug class is covered — just not this specific product, or not yet
File a Formulary or Step Therapy Exception
Gather documentation and have your prescriber submit the supporting statement
What to Do If Your Request Is Denied
Read the denial reason carefully before responding
Denials for "insufficient documentation" need a different response than denials for "clinical criteria not met." Match your appeal to the specific reason cited.
File an internal appeal with new or expanded documentation
For Medicare Part D, this is called a redetermination and must be decided within 7 days standard or 72 hours expedited. Commercial plans use similar internal appeal processes, typically with comparable timeframes.
Escalate to an independent external review if the internal appeal fails
For Medicare Part D, an upheld denial automatically forwards to the Part D Independent Review Entity. For commercial plans, you generally have the right to request an external review conducted by a party unaffiliated with your insurer, typically within four months of the final internal denial.
Ask your prescriber's office about a peer-to-peer review
Many plans allow your prescriber to speak directly with the plan's medical reviewer by phone, which can resolve documentation ambiguities faster than a written appeal alone.
Explore manufacturer support if the appeal path stalls
Lilly's savings card can lower cost for commercially insured patients who have some coverage, and LillyDirect's self-pay vial pricing offers a fallback option while an appeal is pending.
Common Mistakes That Get Requests Denied
- Filing a formulary exception when the real issue is a categorical plan exclusion no exception can override.
- Submitting a generic medical necessity letter that doesn't name the specific formulary alternative or explain why it won't work for this patient.
- Leaving out sleep study documentation when requesting coverage under the OSA indication.
- Not requesting expedited review when the clinical situation genuinely warrants it.
- Confusing the Medicare OSA pathway with the separate GLP-1 Bridge demonstration, and submitting documentation for the wrong one.
- Assuming a denial is final without checking whether an internal appeal or peer-to-peer review is still available.
The difference between a denied and an approved request is almost always documentation specificity, not the number of times you ask. One complete, targeted submission outperforms three vague ones.
Bottom Line
A formulary exception for Zepbound works when the barrier is a formulary placement decision or a utilization restriction like step therapy — and it fails when the real barrier is a categorical plan exclusion of anti-obesity medications, since that's a benefit design choice no exception process can reach. Between now and the October 1, 2026 CVS Caremark reinstatement, most patients on affected commercial plans still need to file this request to keep or start Zepbound rather than switching to Wegovy.
Getting it approved comes down to a specific, complete supporting statement: clear clinical documentation of why the formulary alternative won't work, and — for OSA patients — an explicit citation of Zepbound's unique FDA approval for that condition. Get the documentation right the first time, and most approvals happen well within the standard decision window.
Frequently Asked Questions
A formulary exception is a formal request asking your health plan to cover Zepbound even though it isn't on your plan's list of covered drugs, or to waive a restriction like step therapy that would otherwise require you to try a different medication first. Your prescriber submits a supporting statement explaining why Zepbound specifically, rather than a formulary alternative, is medically necessary for you.
Many commercial plans, including those managed by CVS Caremark, removed Zepbound from their standard formularies in mid-2025 in favor of Wegovy as the preferred GLP-1 for weight management, largely for cost and rebate reasons. Separately, a large number of employer-sponsored plans exclude anti-obesity medications as a category entirely, regardless of which specific drug is requested. CVS Caremark has announced plans to add Zepbound back as a co-preferred option effective October 1, 2026.
For Medicare Part D plans, the plan must decide within 72 hours of receiving your prescriber's supporting statement for a standard request, or 24 hours for an expedited request. Commercial plans don't follow one universal timeline, but ERISA claims rules generally require urgent pre-service claims to be decided as soon as possible and no later than 72 hours, with non-urgent requests typically decided within 15 days.
Standard Medicare Part D does not cover Zepbound for weight loss alone because federal law excludes anti-obesity medications from Part D coverage. Medicare Part D may cover Zepbound when it's prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity, which is a separate FDA-approved indication. Separately, a temporary CMS demonstration called the Medicare GLP-1 Bridge program began providing access to the Zepbound KwikPen for weight loss at a flat monthly copay for eligible beneficiaries starting July 1, 2026, and is scheduled to run through December 31, 2027.
You can file an internal appeal (called a redetermination for Medicare Part D plans), which must include any new supporting clinical documentation. If the internal appeal is also denied, you generally have the right to an independent external review by a party not affiliated with your insurer. For Medicare Part D, the appeal escalates automatically through the Independent Review Entity if the plan upholds its denial.
Usually not. A formulary exception addresses a plan's decision to exclude one specific drug while still covering the drug class, or to place a drug behind a restriction like step therapy. If your plan has a categorical exclusion for the entire anti-obesity drug class written into the plan document, a formulary exception request typically cannot override that exclusion, since it isn't a formulary placement issue — it's a benefit design decision.
No. Zepbound (tirzepatide) and Wegovy (semaglutide) are different molecules with different manufacturers, and plans frequently prefer one over the other for cost and rebate reasons rather than clinical reasons. For most weight-management indications, plans treat them as therapeutic alternatives, which is exactly why a formulary exception is needed to get the non-preferred option covered. For obstructive sleep apnea specifically, they are not interchangeable, since only Zepbound carries that FDA approval.
Generally no. Most exceptions are approved for the remainder of the current plan year, and formularies can change annually, so a new request — or confirmation that the drug has been added to the formulary, as CVS Caremark has announced for October 2026 — is typically required each plan year.
How We Researched This Guide
References
- Centers for Medicare & Medicaid Services. Part D Coverage Determinations, Appeals, and Grievances Guidance.
- U.S. Food and Drug Administration. Zepbound (Tirzepatide) Prescribing Information and Approved Indications.
- U.S. Department of Labor. ERISA Claims Procedure Regulations (29 CFR 2560.503-1).
- Medicare Rights Center. Medicare Interactive: Part D Coverage Determinations and Exceptions.
Suggested additional sources (not embedded — verify before publishing live):
[External Link: CVS Caremark's official 2026 formulary change bulletin confirming the October 1, 2026 Zepbound reinstatement] — omitted because CVS Caremark's formulary bulletins are typically distributed to plan sponsors and members directly rather than published at a single stable public URL.
[External Link: CMS's official Medicare GLP-1 Bridge demonstration program page] — omitted because the demonstration is newly launched and its permanent public URL structure could not be verified at the time of writing.
Related Resources
Related Refill Relay Guides
- [Internal Link: How to Appeal a Denied Zepbound Prior Authorization]
- [Internal Link: Zepbound vs Wegovy: Coverage, Cost, and Clinical Differences]
- [Internal Link: Copay Accumulator vs Maximizer — How Each Affects What You Pay]
- [Internal Link: Medicare GLP-1 Bridge Program (2026): Eligibility and How to Enroll]
- [Internal Link: Can Medicare Patients Use Patient Assistance Programs?]
- [Internal Link: Zepbound Savings Card vs LillyDirect Self-Pay: Which Costs Less?]
- [Internal Link: How to Read Your Explanation of Benefits (EOB) for Specialty Drugs]
Editorial Policy: Refill Relay content is researched using publicly available regulatory materials, manufacturer and pharmacy benefit manager formulary notices, and standard industry appeals practices. Every article is reviewed for clarity, accuracy and usefulness before publication. This content is educational and is not legal or medical advice specific to your individual plan or condition.